Anti-DFNA5/GSDME antibody [EPR19859] - N-terminal,Abcam,AB215191
Anti-DFNA5/GSDME antibody [EPR19859] - N-terminal (ab215191) was developed by Abcam using patented rabbit monoclonal antibody technology and is validated for use in Flow Cyt (Intra), IP and WB. Anti-DFNA5/GSDME antibody [EPR19859] - N-terminal (ab215191) was first used in a scientific publication in 2017 and has been cited over 153 times in peer reviewed journals. It's performance in Western blot in mouse samples is trusted by the scientific community. Abcam's high quality manufacturing and validation processes ensure Anti-DFNA5/GSDME antibody [EPR19859] - N-terminal (ab215191) has high sensitivity and specificity alongside high lot-to-lot consistency and reproducibility. The specificity of Anti-DFNA5/GSDME antibody [EPR19859] - N-terminal (ab215191) has been confirmed by Western Blot testing in DFNA5/GSDME knockout SGC-7901 cells. Anti-DFNA5/GSDME antibody [EPR19859] - N-terminal (ab215191) has 4 independent reviews from customers. Anti-DFNA5/GSDME antibody [EPR19859] - N-terminal (ab215191) specifically detects DFNA5/GSDME (UniProt ID: O60443; Molecular weight: 55kDa) and is sold in 100 µL and 1 mL selling sizes. Conjugation-ready, carrier free format available for antibody clone EPR19859 - ab223877 . Antibody clone EPR19859 is also available pre-conjugated to a variety of labels for your convenience - Alexa Fluor ® 488, PE ( ab225519 , ab225520 ). Gasdermin E (GSDME) plays a significant role in immunology by modulating the immune response, particularly through its involvement in pyroptosis, a form of programmed cell death Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies .
Host
Rabbit
Reactivity
Mouse, Rat, Human
Application
Flow Cyt (Intra), IP, WB
Platform ID
BAB656396716
Abcam
Contact
Tel: +44 (0)1223 696000
Fax: +44 (0)1223 215 215
Email:
Specifications
Scientific Background
Target data Gasdermin-E. Precursor of a pore-forming protein that converts non-inflammatory apoptosis to pyroptosis (PubMed : 27281216, PubMed : 28459430, PubMed : 33852854, PubMed : 35594856, PubMed : 36607699). This form constitutes the precursor of the pore-forming protein : upon cleavage, the released N-terminal moiety (Gasdermin-E, N-terminal) binds to membranes and forms pores, triggering pyroptosis (PubMed : 28459430).. Gasdermin-E, N-terminal. Pore-forming protein produced by cleavage by CASP3 or granzyme B (GZMB), which converts non-inflammatory apoptosis to pyroptosis or promotes granzyme-mediated pyroptosis, respectively (PubMed : 27281216, PubMed : 28459430, PubMed : 32188940, PubMed : 33852854, PubMed : 35594856). After cleavage, moves to the plasma membrane, homooligomerizes within the membrane and forms pores of 10-15 nanometers (nm) of inner diameter, allowing the release of mature interleukins (IL1B and IL16) and triggering pyroptosis (PubMed : 28459430, PubMed : 32188940, PubMed : 33852854, PubMed : 35594856). Binds to inner leaflet lipids, bisphosphorylated phosphatidylinositols, such as phosphatidylinositol (4,5)-bisphosphate (PubMed : 28459430). Cleavage by CASP3 switches CASP3-mediated apoptosis induced by TNF or danger signals, such as chemotherapy drugs, to pyroptosis (PubMed : 27281216, PubMed : 28459430, PubMed : 32188940). Mediates secondary necrosis downstream of the mitochondrial apoptotic pathway and CASP3 activation as well as in response to viral agents (PubMed : 28045099). Exhibits bactericidal activity (PubMed : 27281216). Cleavage by GZMB promotes tumor suppressor activity by triggering robust anti-tumor immunity (PubMed : 21522185, PubMed : 32188940). Suppresses tumors by mediating granzyme-mediated pyroptosis in target cells of natural killer (NK) cells : cleavage by granzyme B (GZMB), delivered to target cells from NK-cells, triggers pyroptosis of tumor cells and tumor suppression (PubMed : 31953257, PubMed : 32188940). May play a role in the p53/TP53-regulated cellular response to DNA damage (PubMed : 16897187).. Gasdermin-E, N-terminal. (Microbial infection) Pore-forming protein, which promotes maternal placental pyroptosis in response to Zika virus infection, contributing to adverse fetal outcomes. See full target information GSDME
Category Paths
- Products>Primary Antibodies>Monoclonal Antibodies
- Products>Primary Antibodies>Recombinant Antibodies
Please provide the required information below so that we can quickly source your products.